I S H P S p r i n g C o n f e r e n c e Megan Koyle, PharmD Elaine Nguyen, PharmD, MPH, BCPS
|
|
- Leonard Garrett
- 5 years ago
- Views:
Transcription
1 I S H P S p r i n g C o n f e r e n c e Megan Koyle, PharmD Elaine Nguyen, PharmD, MPH, BCPS
2 Objectives Increase foundational knowledge of HIV/AIDS through greater awareness of epidemiology, pathophysiology, and related disease background topics Describe how HIV is transmitted and apply this information to better understand safety precautions and prevention measures Recognize HIV/AIDS testing methods, treatment options, and the technician role in assisting patients with the disease
3 Outline Background Workplace Safety Testing Treatment Technician Opportunities
4
5 Epidemiology The CDC estimates that >1.1 million people over the age 13 are living with HIV infection in the U.S. Almost 16% of those are currently unaware of their infection Over the past decade, the number of new HIV infections in the U.S. has remained relatively stable at about 50,000 per year For patients in some rural communities easy access to physicians, hospitals and community health centers prevents testing and treatment Exploring and Defining the Community Pharmacists Role in HIV Prevention, Testing and Care [Internet]. Washington, DC: American Pharmacists Association; [cited 2015 March 7]. Available from:
6 HIV in the U.S.
7 HIV Incidence 1 case 7 cases 1 case 1 case 1 case
8 Origin of HIV Scientists identified a type of chimpanzee in West Africa as the source of HIV infection in humans Theory: Simian immunodeficiency virus (SIV) was transmitted to humans and mutated into HIV when humans hunted these chimpanzees for meat and came into contact with their infected blood Studies show that HIV may have jumped from apes to humans as far back as the late 1800s
9 Timeline of HIV/AIDS December 10: The CDC reports a case President Obama June 5: The CDC reports cases of a rare March 19: FDA approves FDA approves the first the first The protease CDC reports the first of AIDS in an infant antiretroviral who received drug, blood announces Newly elected accelerated President lung infection in five young, previously inhibitor. zidovudine This ushers substantial in a new decline June in AIDS 5: 25 deaths year anniversary Barack transfusions. The following (AZT) and week, FDA 22 efforts Obama to increase calls for the the healthy, gay men. These reports mark declares era of HAART. HIV By in the the end U.S. of Due largely since the to the first use AIDS cases of prevention unexplained availability development cases were of treatment of the first the first official reports of what will as a new the indication year, 500,000 for of cases HAART, of AIDS AIDS-related deaths reported. in National immunodeficiency and opportunistic to people HIV/AIDS living with Strategy become known as the AIDS epidemic. male condoms. have been reported the in U.S. the decline U.S. by 47% compared infections in infants were reported. HIV/AIDS for the in the U.S. with the previous year. U.S A time line of AIDS [Internet]. Washington, DC: US Department of Health and Human Services; [updated 2011; cited 2015 March 7]. Available from:
10 What is HIV? HIV stands for Human Immunodeficiency Virus H Human This particular virus can only infect human beings I Immunodeficiency HIV weakens your immune system by destroying cells that fight disease and infection V Virus A virus can only reproduce itself by taking over a cell in the body of its host WHAT IS HIV/AIDS? [Internet]. Washington, DC: US Department of Health and Human Services; [updated 2014 April 29; cited 2015 March 7]. Available from:
11 What is AIDS? AIDS stands for Acquired Immunodeficiency Syndrome A Acquired You acquire AIDS after birth, it is not inherited I Immuno Your body's immune system D Deficiency You get AIDS when your immune system is deficient S Syndrome A syndrome is a collection of symptoms and signs of disease WHAT IS HIV/AIDS? [Internet]. Washington, DC: US Department of Health and Human Services; [updated 2014 April 29; cited 2015 March 7]. Available from:
12 HIV Transmission How do you get HIV or AIDS? [Internet]. Washington, DC: US Department of Health and Human Services; [updated 2014 Jun 6; cited 2015 Feb 22]. Available from:
13 Pathophysiology of HIV The Pathophysiology of HIV[Internet]. [Updated 2011 Oct 25 ; cited 2015 March 7]. Available from:
14 Signs and Symptoms Signs and Symptoms [Internet]. Washington, DC: US Department of Health and Human Services; [updated 2014 April 29; cited 2015 March 7]. Available from:
15 Signs and Symptoms Initial symptoms Fever (this is the most common symptom) Swollen glands Sore throat Rash Fatigue Muscle and joint aches and pains Headache
16 Signs and Symptoms The clinical latency stage Virus is replicating without producing symptoms Also called asymptomatic HIV infection People in this symptom-free period are still able to transmit HIV to others
17 Trivia The clinical latency period can last
18 Signs and Symptoms Progression to AIDS Rapid weight loss Recurring fever or profuse night sweats Extreme and unexplained tiredness Prolonged swelling of the lymph glands in the armpits, groin, or neck Diarrhea that lasts for more than a week Sores of the mouth, anus, or genitals Pneumonia Red, brown, pink, or purplish blotches on or under the skin or inside the mouth, nose, or eyelids Memory loss, depression, and other neurologic disorders
19 Outline Background Workplace Safety Testing Treatment Technician Opportunities
20 HIV Transmission Body fluids Blood Semen (cum) Pre-seminal fluid (pre-cum) Rectal fluids Vaginal fluid Breast milk How do you get HIV or AIDS? [Internet]. Washington, DC: US Department of Health and Human Services; [updated 2014 Jun 6; cited 2015 Feb 22]. Available from:
21 HIV Transmission Occupational transmission is very rare How do you get HIV or AIDS? [Internet]. Washington, DC: US Department of Health and Human Services; [updated 2014 Jun 6; cited 2015 Feb 22]. Available from:
22 Trivia In what year was the last confirmed case of occupational HIV transmission in the United States? If exposed to HIV-infected blood at work, what is a health care workers risk of becoming infected? HIV/AIDS: Occupational HIV Transmission and Prevention Among Health Care Workers [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; [updated 2014 Jan 7; cited 2015 Feb 22]. Available from:
23 Infection Control Precautions HIV/AIDS: Occupational HIV Transmission and Prevention Among Health Care Workers [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; [updated 2014 Jan 7; cited 2015 Feb 22]. Available from:
24 Post-Exposure Prophylaxis Start post-exposure prophylaxis (PEP) as soon as possible! Source patient testing Three (or more) medications recommended Preferred PEP regimen: emtricitabine + tenofovir + raltegravir Consider side effects, drug interactions, etc. Source patient and drug-resistant HIV Complete 4 weeks of therapy Kuhar DT, Henderson DK, Struble KA, et al. for the US Public Health Service Working Group. Updated US Public Health Service Guidelines for the Management of Occupational Exposure to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis. Infect Contro Hosp Epidemiol. 2013;34:
25 Post-Exposure Prophylaxis Within 72 hours Counseling Post-exposure testing Medical evaluation Follow-up testing Initial 6 weeks 12 weeks 6 months Drug toxicity monitoring: blood count, renal function, liver function Baseline 2 weeks PEPline: Kuhar DT, Henderson DK, Struble KA, et al. for the US Public Health Service Working Group. Updated US Public Health Service Guidelines for the Management of Occupational Exposure to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis. Infect Contro Hosp Epidemiol. 2013;34:
26 Outline Background Workplace Safety Testing Treatment Technician Opportunities
27 Trivia at least HIV Testing Frequency[Internet]. Washington, DC: US Department of Health and Human Services; [updated 2014 Jun 6; cited 2015 Feb 22]. Available from:
28 Risky Behaviors Sharing needles, syringes, etc. History of sexual transmitted disorders Unprotected sex with multiple or anonymous partners Testing may be recommended more often HIV Testing Frequency[Internet]. Washington, DC: US Department of Health and Human Services; [updated 2014 Jun 6; cited 2015 Feb 22]. Available from:
29 Ways to Test for HIV Antibody test Enzyme immunoassay Blood, oral fluid, urine Results can take up to 2 weeks Rapid HIV antibody Blood, oral fluid, urine Results take minutes Require confirmatory test Types of HIV Tests [Internet]. Washington, DC: US Department of Health and Human Services; [updated 2014 Jun 6; cited 2015 Feb 27]. Available from:
30 Ways to Test for HIV Antigen test (p24) Blood Can detect HIV 1-3 weeks after infection Usually done in combination with antibody test Polymerase chain reaction (PCR) test Can detect HIV 2-3 weeks after infection Used to measure viral loads Types of HIV Tests [Internet]. Washington, DC: US Department of Health and Human Services; [updated 2014 Jun 6; cited 2015 Feb 27]. Available from:
31 Home Testing Home Access HIV-1 Test System OraQuick In-Home HIV Test
32
33
34 Home Access HIV-1 Test System 1. Register code number 2. Collect blood specimen 3. Ship blood specimen 4. Get results HIV-1 Test Demo [Internet]. Hoffman Estates (IL): Home Access Health; 2008 [cited 2015 Feb 27]. Available from:
35 OraQuick In-Home HIV Test
36 OraQuick In-Home HIV Test OraQuick : Before You Begin [Internet]. Bethleham (PA): OraSure Technologies, Inc.; 2014 [cited 2015 Feb 27]. Available from:
37 OraQuick : How Oral Testing Works [Internet]. Bethleham (PA): OraSure Technologies, Inc.; 2014 [cited 2015 Feb 27]. Available from:
38 Outline Background Workplace Safety Testing Treatment Technician Opportunities
39 Treatment Goals Reduce HIV-associated morbidity and mortality Restore and preserve immunologic function Suppress HIV viral load Prevent transmission Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [Internet]. Washington, DC: Department of Health and Human Services; 2012 [updated 2012 Mar 27, cited 2015 Mar 1]. Available from:
40 Tests CD4 cell count and percentage Stage disease Determine opportunistic infection risk and when to begin prophylactic medications Urgency and response to therapy Plasma HIV RNA (viral load) Response to therapy and a lot more! Aberg JA, Gallant JE, Ghanem, K, et al. Primary Care Guidelines for the Management of Persons Infected with HIV: 2013 Update by the HIV Medicine of the Infectious Diseases Society of America. Clin Infect Disease. 2014;58:e1-34.
41 Initiating Therapy in Treatment-Naïve Patients Begin therapy to reduce the risk of disease progression: CD4 Count Panel Recommendation < 350 cells/mm 3 AI 350 to 500 cells/mm 3 AII > 500 cells/mm 3 BIII Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [Internet]. Washington, DC: Department of Health and Human Services; 2014 [updated 2014 May 1, cited 2015 Mar 1]. Available from:
42 Initiating Therapy in Treatment-Naïve Patients Begin therapy when HIV positive and Pregnant Diagnosed with AIDS Have HIV-associated nephropathy Co-infected with hepatitis B or hepatitis C Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [Internet]. Washington, DC: Department of Health and Human Services; 2014 [updated 2014 May 1, cited 2015 Mar 1]. Available from:
43 Initiating Therapy in Treatment-Naïve Patients Begin therapy to prevent transmission: Transmission Risk Perinatal Heterosexual Other Panel Recommendation AI AI AIII Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [Internet]. Washington, DC: Department of Health and Human Services; 2014 [updated 2014 May 1, cited 2015 Mar 1]. Available from:
44 Initiating Therapy in Treatment-Naïve Patients Patients starting ART should be willing and able to commit to treatment and understand the benefits and risks of therapy and the importance of adherence (AIII). Patients may choose to postpone therapy, and providers, on a case-by-case basis, may elect to defer therapy on the basis of clinical and/or psychosocial factors. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [Internet]. Washington, DC: Department of Health and Human Services; 2014 [updated 2014 May 1, cited 2015 Mar 1]. Available from:
45 HIV Web Study: Antiretrovial Rx, Discussion [Internet]. Seattle (WA): University of Washington; 2013 [cited 2015 Mar 1]. Available from:
46 Antiretroviral Therapy (ART) Medication Classes Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Protease inhibitors (PIs) Integrase inhibitors (InSTIs) Entry inhibitors Fusion inhibitors CCR5 antagonists
47 HIV Web Study: Antiretrovial Rx, Discussion [Internet]. Seattle (WA): University of Washington; 2013 [cited 2015 Mar 1]. Available from:
48 NRTIs Abacavir sulfate (ABC) Didanosine (ddi) Emtricitabine (FTC) Lamivudine (3TC) Stavudine (d4t) Tenofovir (TDF) Zidovudine (AZT or ZDV) Most are eliminated by the kidneys Adverse effects Peripheral neuropathy Pancreatitis Lipoatrophy Myopathy Anemia Life-threatening acidosis with fatty liver (rare) Resistance reported for all NRTIs Anderson PL, Kakuda TN, Fletcher CV. Chapter 103. Human Immunodeficiency Virus Infection. In: DiPiro JT, Talbert RL, Yee GC, et al. eds. Pharmacotherapy: A Pathophysiological Approach, 9e. New York (NY): McGraw-Hill; 2014 [cited 2015 Mar 1]. Available from:
49 NNRTIs Efavirenz (EFV) Etravirine (ETR) Delaviridine (DLV) Nevirapine (NVP) Rilpivirine (RPV) Mainly eliminated by the liver and/or gut metabolism through cytochrome P450 (CYP) enzyme system Adverse effects Rash Elevated liver function tests Low genetic barrier to resistance Anderson PL, Kakuda TN, Fletcher CV. Chapter 103. Human Immunodeficiency Virus Infection. In: DiPiro JT, Talbert RL, Yee GC, et al. eds. Pharmacotherapy: A Pathophysiological Approach, 9e. New York (NY): McGraw-Hill; 2014 [cited 2015 Mar 1]. Available from:
50 PIs Atazanavir (ATV) Darunavir (DRV) Fosamprenavir (FPV) Indinavir (IDV) Mainly eliminated by the liver and/or gut metabolism through cytochrome P450 (CYP) enzyme system CYP3A Often always boosted with ritonavir or cobicistat Lopinavir (LPV) Nelfinavir (NFV) Adverse effects Gastrointestinal distress Metabolic changes Ritonavir (RTV) High genetic barrier to resistance Saquinavir (SQV) Tipranavir (TPV) Anderson PL, Kakuda TN, Fletcher CV. Chapter 103. Human Immunodeficiency Virus Infection. In: DiPiro JT, Talbert RL, Yee GC, et al. eds. Pharmacotherapy: A Pathophysiological Approach, 9e. New York (NY): McGraw-Hill; 2014 [cited 2015 Mar 1]. Available from:
51 InSTIs Raltegravir (RAL) Elvitegravir (EVG) Dolutegravir (DTG) RAL and DTG No issues with CYP drug interactions EVG Metabolized by CYP3A Co-formulated with cobicistat Anderson PL, Kakuda TN, Fletcher CV. Chapter 103. Human Immunodeficiency Virus Infection. In: DiPiro JT, Talbert RL, Yee GC, et al. eds. Pharmacotherapy: A Pathophysiological Approach, 9e. New York (NY): McGraw-Hill; 2014 [cited 2015 Mar 1]. Available from:
52 Entry Inhibitors Enfuviritide (ENF) Fusion inhibitor Subcutaneous injection Adverse effects Injection-site reactions Maraviroc CCR5 antagonists Only effective against R5 virus, need to test for before use CYP3A and P-glycoprotein substrate, watch out for interactions Anderson PL, Kakuda TN, Fletcher CV. Chapter 103. Human Immunodeficiency Virus Infection. In: DiPiro JT, Talbert RL, Yee GC, et al. eds. Pharmacotherapy: A Pathophysiological Approach, 9e. New York (NY): McGraw-Hill; 2014 [cited 2015 Mar 1]. Available from:
53 Preferred Initial Regimens Regimens consist of two NRTIs + another ARV class NNRTI-based regimen EFV + TDF + FTC PI-based regimens ATV/r + TDF + FTC DRV/r + TDF + FTC InSTI-based regimens DTG + ABC + 3TC only if HLA-B*5701 negative DTG + TDF + FTC EVG + TDF + FTC EVG/cobi + TDF + FTC only if CrCl > 70mL/min RAL + TDF + FTC Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [Internet]. Washington, DC: Department of Health and Human Services; 2014 [updated 2014 May 1, cited 2015 Mar 1]. Available from:
54 Opportunistic Infections Smith CL. HIV/Infectious Diseases. In: ACCP Updates in Therapeutics 2014: Pharmacotherapy Preparatory Review and Recertification Course. Lenexa (KS): ACCP; 2014.
55 Outline Background Workplace Safety Testing Treatment Technician Opportunities
56 Referring Patients Planned Parenthood 3668 North Harbor Lane Boise, ID The Community Center 305 E. 37th Street Garden City, ID A.L.P.H.A. of Boise 575 N. 8th St. Boise, ID Central District Health Dept. 707 N Armstrong Pl Boise, ID Testing Centers BSU Health Wellness Center Norco Building Boise, ID 83725
57 Donation Encouraging your pharmacy to donate test kits: Allies Linked for the Prevention of HIV and AIDS (A.L.P.H.A.) Tests costs approximately $15 A.L.P.H.A. is a 501(c)3 nonprofit corporation Donations or in-kind donations are taxdeductible
58 Professional Training A.L.P.H.A. Receive training on how to perform waived rapid HIV testing in the community Contact Judy Thorne at Idaho Department of Health and Welfare Passport to Partner Services - Date: May HIV and HCV Update: Corrections to Community - Date: May 27
59 Providing Resources The Idaho Ryan White Part B Program (RWPB) HIV diagnostic and monitoring labs to uninsured clients Emergency financial assistance Medical transportation Psychosocial support services Linguistic services and referral for health care services to all clients meeting eligibility criteria
60 Providing Resources Patient Assistance and Co-Pay Programs for HIV and Viral Hepatitis Drugs These programs offer assistance to people with private health insurance for the copayments required to obtain HIV drugs at the pharmacy
61
Continuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationI. HIV Epidemiology. HIV Infection A Primer. Objectives. Disclosures 7/18/2014
Objectives HIV Infection A Primer Discuss the worldwide and domestic epidemiology of HIV infection Review HIV Biology Review HIV Transmission and Prevention Review HIV diagnosis Describe the approaches
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationNorthwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care
Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care www.nwaetc.org The Northwest AIDS Education and Training Center (NW AETC), located at the University
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationOverview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course
Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED Acknowledgments - Dr. Christina Polyak - Dr. Julie Ake Disclaimer The views expressed in this presentation are
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationHIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014
Objectives HIV Update 2014 Jay Sizemore, MD, MPH Medical Director Chattanooga CARES Assistant Professor UTCOM Chattanooga 2October 2014 Review HIV epidemiology and screening/testing guidelines Discuss
More informationWhen to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc
When to Start ART Exact CD4 count at which to initiate therapy not known, but evidence points to starting at higher counts Current recommendation: ART for all patients with CD4 count of
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationHIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationOverview of HIV. LTC Paige Waterman
Overview of HIV LTC Paige Waterman Outline Background and Epidemiology HIV Virology, Transmission, and Pathogenesis Acute HIV infection HIV Diagnostics Management of Health Care Personnel Exposed to HIV
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationThe ART of Managing Drug-Drug Interactions in Patients with HIV
The ART of Managing Drug-Drug Interactions in Patients with HIV Bradley L. Smith, Pharm.D. smith.bradley1@mayo.edu Pharmacy Grand Rounds December 19, 2017 2017 MFMER slide-1 Presentation Objectives Describe
More informationHIV Overview. Mary Marovich, MD, DTMH Division of Retrovirology Walter Reed Army Ins?tute of Research US Military HIV Research Program
HIV Overview Mary Marovich, MD, DTMH Division of Retrovirology Walter Reed Army Ins?tute of Research US Military HIV Research Program www.hivresearch.org 1 Outline HIV Virology, Transmission, and Pathogenesis
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More information/AIDS HIV/ HIV Overview. Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program
/AIDS HIV/ HIV Overview Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program www.hivresearch.org 1 WRAIR Tropical Medicine Course
More informationHuman Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications
Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications Carrie Allen PharmD, CGP, BCPS, BCPP, CCHP Overview - Part 2: HIV
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationUpdate on Antiretroviral Treatment for HIV Infection 2008
Update on Antiretroviral Treatment for HIV Infection 2008 Janet Gilmour MD FRCP(C) Clinical Associate Professor of Medicine University of Calgary November 2008 Disclosure and Acknowledgements Disclosure:
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
Generic Name COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir)
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationAn HIV Update Jan Clark, PharmD Specialty Practice Pharmacist
An HIV Update - 2019 Jan Clark, PharmD Specialty Practice Pharmacist 2 The goal of this program is to provide a review and update of HIV care and to provide a forum for discussing the current local and
More informationHIV Management Update 2015
9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationHIV Diagnosis and Management 2015 Update. Faria Farhat, MD MedStar Washington Hospital Center
HIV Diagnosis and Management 2015 Update Faria Farhat, MD MedStar Washington Hospital Center Objectives Describe the epidemiology and pathogenesis of HIV infection Highlight HIV diagnosis algorithm and
More informationHIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship
HIV basics Katya Calvo Medical Director of Antimicrobial Stewardship Learning Objectives 1. Review of HIV epidemiology worldwide and locally 2. Review of recommendations on whom to screen 3. Work up of
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationAcquired Immune Deficiency Syndrome (AIDS)
Acquired Immune Deficiency Syndrome (AIDS) By Jennifer Osita Disease The disease I am studying is AIDS (Acquired Immune Deficiency Syndrome) which is when the immune system is too weak to fight off many
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationHIV/AIDS HIV/AIDS: Outline. Morbidity and Mortality Weekly Report (MMWR)
HIV/AIDS: Outline HIV/AIDS 2013 Roy M. Gulick, MD, MPH Professor of Medicine Chief, Division of Infectious Diseases Weill Medical College of Cornell University New York City January 31, 2013 Epidemiology
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationHIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationCLAUDINE HENNESSEY & THEUNIS HURTER
HIV/AIDS/TB CLAUDINE HENNESSEY & THEUNIS HURTER KEY TERMS Do these sound familiar? What strange terms do you hear in the clinics? Any others to add?? HIV AIDS Viral Load & suppression CD4 count Regimen
More informationEpidemiology Testing Clinical Features Management
Jason Cronin, MD Epidemiology Testing Clinical Features Management In 1981, 1 the first cases of AIDS were identified among gay men in the US. However, scientists later found evidence that the disease
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationPage 1. Outline. Outline. Building specialized knowledge: HIV. Biological interactions. Social aspects of the epidemic. Programmatic actions
Harvard-Brazil Collaborative Public Health Field Course January 2014 Lecture # 8 Building specialized knowledge: HIV Aluisio Segurado Department of Infectious Diseases School of Medicine, University of
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationTORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION
TGH - ambulatory rotation page 1 of 5 TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION SITE: Immunodeficiency Clinic, Toronto General Hospital, University Health Network Location: 13 th floor, Norman
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir) Stavudine
More informationHIV for the Non-ID Pharmacist
Disclosures HIV for the Non-ID Pharmacist I have nothing to disclose at this time Carmen Faulkner-Fennell, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist--Infectious Diseases Greenville Hospital System
More informationAntiretroviral Therapy During Pregnancy and Delivery: 2015 Update
Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,
More informationHIV medications HIV medication and schedule plan
Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with
More informationOverview of HIV. Christina Polyak, MD, MPH. Research Physician. U.S. Military HIV Research Program, Walter Reed Army Institute of Research
Overview of HIV Christina Polyak, MD, MPH Research Physician U.S. Military HIV Research Program, Walter Reed Army Institute of Research The views expressed are those of the authors and should not be construed
More informationPediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,
More informationNothing to disclose.
Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital HIV UPDATE FOR THE PRIMARY CARE PROVIDER Nothing to disclose. 1 Outline Epidemiology Screening / testing for HIV
More informationSEXUALLY TRANSMITTED DISEASES (INFECTIONS)
SEXUALLY TRANSMITTED DISEASES (INFECTIONS) HIV/AIDS - TRANSMISSION Sexual intercourse Anal, oral, & vaginal Multiple partners Sharing needles Mother to infant Born or breast milk Blood transfusions Open
More informationNobel /03/28. HIV virus and infected CD4+ T cells
Mechanism of HIV drug resistance. Rodrigo Brindeiro / Amilcar Tanuri Laboratório de Virologia Molecular UFRJ 2 -Asso ciate Research Scientist, Internatio nal Center fo r Aids Care and Treatment Programs-ICAP,
More informationPreventing Mother to Child HIV Transmission: Are We There Yet?!'
Preventing Mother to Child HIV Transmission: Are We There Yet?!' 2017 Michigan Clincal Nursing Conference for HIV and STD Care May 18, 2017 Frankenmuth MI 1 Theodore B. Jones, MD Maternal Fetal Medicine
More informationNON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS IN HIV PREVENTION. Jason E. Vercher, PA-C, AAHIVM
NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS IN HIV PREVENTION Jason E. Vercher, PA-C, AAHIVM Disclosures No disclosures to report Learning Objectives q Identify Individuals who would benefit from non-occupational
More informationANTIRETROVIRAL TREATMENTS (Part 1of
CCR5 CO-RECEPTOR ANTAGONISTS maraviroc (MVC) Selzentry 25mg, 75mg, FUSION INHIBITORS 20mg/mL ANTIRETROVIRAL TREATMENTS (Part 1of 5) oral soln enfuvirtide (ENF, T-20) Fuzeon 90mg/mL pwd for SC inj after
More informationHIV Treatment: State of the Art 2013
HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial
More informationApproach for the Newly Diagnosed HIV Positive Patient
Approach for the Newly Diagnosed HIV Positive Patient Jason E. Farley, PhD, MPH, ANP-BC, FAAN, AACRN Associate Professor & NP, Johns Hopkins University School of Nursing & Medicine Director, AETC Adult-Gerontology
More informationTB Intensive Tyler, Texas December 2-4, Tuberculosis and HIV Co-Infection. Lisa Y. Armitige, MD, PhD. December 4, 2008.
TB Intensive Tyler, Texas December 2-4, 2008 Tuberculosis and HIV Co-Infection Lisa Y. Armitige, MD, Ph.D. December 4, 2008 Tuberculosis and HIV Co Infection Lisa Y. Armitige, MD, PhD Assistant Professor
More informationOptimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
More informationFOCUS ON HIV. By Christine Elliott, BScPhm, RPh
Therapeutic Options FOCUS ON HIV By Christine Elliott, BScPhm, RPh BACKGROUND The human immunodeficiency virus type 1 (HIV-1) was first discovered in 1982. 1 A global pandemic followed, with an estimated
More informationHIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop
HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop Parya Saberi, PharmD, MAS The Medical Management of HIV/AIDS December 2012 Objectives What are commonly used ARVs and where do they work in
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationThe Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018
The Future of HIV: Advances in Drugs and Research Shauna Gunaratne December 17, 2018 Overview Epidemiology Science of HIV How HIV treatment and management have changed over the years New medicines and
More informationStructured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007
Structured Treatment Interruption in HIV Positive Patients Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007 Objectives To become re-acquainted with the basics of HAART for HIV infection
More informationSasisopin Kiertiburanakul, MD, MHS
What s Newin Antiretroviral Therapy? Sasisopin Kiertiburanakul, MD, MHS Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Rotating RCPT,
More informationTB/HIV Co-Infection. Tuberculosis and HIV
TB Intensive Tyler, Texas June 2-4, 2010 TB/HIV Co-Infection Lisa Y Armitige, MD, PhD June 3, 2010 Tuberculosis and HIV Co-Infection Lisa Y Armitige, MD, PhD Medical Consultant Heartland National TB Center
More informationHIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
More informationPHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS
8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI
More informationHIV and contraception the latest recommendations
1 8-11 June 2015, Chiang-Mai HIV and contraception the latest recommendations Mary Lyn Gaffield, Sharon Phillips, Rachel Baggaley, Petrus Steyn, and Marleen Temmerman 2 Medical eligibility criteria for
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationTHE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010
THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010 The South African Antiretroviral Treatment Guidelines 2010 Goals of the programme Achieve best health outcomes in the most cost-efficient manner
More informationHIV infection and Primary Care. HIV Care in /30/2013. It s not the AIDS of 85. Stephen Raffanti MD MPH Vanderbilt University School of Medicine
HIV infection and Primary Care Stephen Raffanti MD MPH Vanderbilt University School of Medicine HIV Care in 2013 Chronic lifelong treatment with all the associated issues: medication tolerability medication
More informationUpdates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017
Mountain West AIDS Education and Training Center Updates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017 26 October 2017 Hillary
More informationPHCP 403 by L. K. Sarki
PHCP 403 by L. K. Sarki objectives To gain insight into the epidemiology of HIV To gain basic understanding of the etiology of HIV disease To know the clinical manifestations of the disease To gain a basic
More informationOverview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course
Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course The opinions or assertions contained herein are the private views of the author, and are not to be construed as official, or
More informationDidactic Series. Update: 2012 HIV Treatment Guidelines. Daniel Lee, MD August 30, 2012
Didactic Series Update: 2012 HIV Treatment Guidelines Daniel Lee, MD August 30, 2012 ACCREDITATION STATEMENT: University of California, San Diego School of Medicine is accredited by the Accreditation Council
More informationThe Global HIV Epidemic. Jerome Larkin, MD
The Global HIV Epidemic Jerome Larkin, MD Outline Global Epidemiology Natural History of HIV Antiretroviral Therapy Malaria Tuberculosis Prevention of Mother to Child Transmission Post-Exposure Prophylaxis
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationHIV Treatment Guidelines
HIV Treatment Guidelines Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Are Treatment Guidelines? Issued by variety of global and country-based
More information2/10/2015. Switching from old regimens. HIV treatment revision: As simple as old versus new? What is an old regimen? What is an old regimen?
Switching from old regimens David Nolan Department of Immunology, Royal Perth Hospital, Western Australia Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia What is
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Initial Therapy for Antiretroviral Naïve HIV Infected Patients Michelle Cespedes, MD, MS Associate Professor of Medicine Division of Infectious Disease Icahn School of Medicine at Mount Sinai Disclosures
More informationOccupational and Non- Occupational HIV Post-exposure Prophylaxis
Occupational and Non- Occupational HIV Post-exposure Prophylaxis Amy V. Kindrick, MD, MPH National Clinicians Post-Exposure Prophylaxis Hotline (PEPline) University of California, San Francisco San Francisco
More informationSELECTING THE BEST ART FOR EACH PATIENT
SELECTING THE BEST ART FOR EACH PATIENT Corklin R Steinhart, MD, PhD Head, Global Medical Directors ViiV Healthcare CNVX/HIVP/0025/16 5th Asian Conference on Hepatitis & AIDS 第五届亚洲肝炎与艾滋病学术会议 28-29 May
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationHIV/AIDS Prenatal Care for HIV+ Mothers. 1. Algorithm for Prenatal Screening & Care (Antepartum)
1. Algorithm for Prenatal Screening & Care (Antepartum) 2. Algorithm for Prenatal HIV Screening and Care (Mother refuses screening) 3. Algorithm for Intrapartum Care 4. Prenatal Care for HIV+ Mothers a.
More informationDistribution and Effectiveness of Antiretrovirals in the Central Nervous System
Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Scott Letendre, MD Associate Professor of Medicine HIV Neurobehavioral Research Center and Antiviral Research Center University
More informationHIV - Therapy Principles
HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV
More informationARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting
ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting Dr. Andrew D Kambugu, FRCP (UK) Infectious Diseases Institute, Makerere University Outline of Discussion Key Definitions
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationFirst line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
More informationHIV Update. Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine
HIV Update Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine Rates of Diagnoses of HIV Infection among Adults and Adolescents, 2012 United States and 6 Dependent
More informationAntiretroviral Therapy
Antiretroviral Therapy Scott M. Hammer, M.D. 1986 1990 ZDV monorx 1990 1995 Alternative NRTI monorx Combination NRTI Rx Introduction of NNRTI s Antiretroviral resistance Pathogenetic concepts Evolution
More informationWESTERN CAPE ART GUIDELINES PRESENTATION 2013
WESTERN CAPE ART GUIDELINES PRESENTATION 2013 The WC guidelines are based on SA National ART guidelines dated 24th March 2013 Acknowledgement goes to members of the Adult and Paediatric HAST policy advisory
More informationGuidelines for Implementing Pre-Exposure Prophylaxis For The Prevention of HIV in Youth Peter Havens, MD MS Draft:
Guidelines for Implementing Pre-Exposure Prophylaxis For The Prevention of HIV in Youth Peter Havens, MD MS Draft: 10-2-2015 Clinical studies demonstrate that when a person without HIV infection takes
More information